Jelly Roll has been open about choosing not to use GLP-1 medications like Wegovy or Zepbound
After consideration of the comments received, we are finalizing our proposal to remove the HCHE measure from the Hospital OQR and REHQR Programs, and the FCHE measure from the ASCQR Program beginning with the CY 2025 reporting period/CY 2027 payment determination
In a healthcare environment already defined by rising costs, the GLP-1 surge presents a critical challenge that requires a strategic, forward-thinking approach to plan design and cost containment
In addition, the authors reported that they observed no inhibition of influx by the GLP-1R antagonist Exendin (939)
As a result, more ROS and RNS are produced by the mitochondria
Read more: #DiabetesCare #SpecialtyPharmacy #HealthcareInnovation #PatientAdherence #WhitePaperComingSoon To view or add a comment, sign in More Relevant Posts On the anniversary of our company's formation, Clearway Health announces initiatives to solve for hospitals operating expense pressures and increased medication costs in a changing legislative and 340B landscape
